<DOC>
	<DOCNO>NCT01741454</DOCNO>
	<brief_summary>The purpose study determine whether combination therapy Tolterodine ER Tamsulosin effective monotherapy tamsulosin alone reduce stent symptom . The investigator hope show addition Tolterodine ER Tamsulosin provide added benefit reduce stent symptom patient unilateral placement ureteral stent . The investigator hypothesize combination therapy tamsulosin tolterodine ER yield great symptom relief tamsulosin alone .</brief_summary>
	<brief_title>Treatment Symptoms After Stent Placement Urinary Tract Obstruction</brief_title>
	<detailed_description>The investigator aim show addition Tolterodine ER Tamsulosin provide add benefit ameliorate stent relate symptom patient unilateral placement ureteral stent urolithiasis . This objective assessed determine mean difference urinary symptom index domain Urinary Stent Symptom Questionnaire , validate tool use assess stent symptoms1 . The investigator felt 15 % decrease index score experimental group , compare control group would represent clinically significant improvement urinary symptom , base prior study evaluate low urinary tract symptom patient stent . The investigator hypothesize combination therapy Tamsulosin Tolterodine ER yield great symptom relief tamsulosin alone .</detailed_description>
	<mesh_term>Ureteral Obstruction</mesh_term>
	<mesh_term>Tamsulosin</mesh_term>
	<mesh_term>Tolterodine Tartrate</mesh_term>
	<mesh_term>Cholinergic Antagonists</mesh_term>
	<criteria>Patients unilateral ureteral stent placement urolithiasis 1 . Preexisting low urinary tract symptom 2 . Active urinary tract infection 3 . Contraindication anticholinergic medication 1 . Prior hypersensitivity allergy tolterodine 2 . Patients severe hepatic impairment ( ChildPugh Class C ) 3 . Patients uncontrolled close ( narrow ) angle glaucoma 4 . Patients urinary retention 4 . Current anticholinergic use 5 . Chronic pelvic pain syndrome ( e.g . acute/chronic prostatitis , interstitial cystitis ) 6 . Pregnant females 7 . Under 18 year age 8 . Prior hypersensitivity allergy tolterodine 9 . Patients severe hepatic impairment ( ChildPugh Class C ) 10 . Patients uncontrolled close ( narrow ) angle glaucoma 11 . Patients urinary retention 12 . Unable provide inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Tolterodine</keyword>
	<keyword>Tamsulosin</keyword>
	<keyword>Ureteral Obstruction</keyword>
</DOC>